Vivos Therapeutics, Inc. (VVOS)
NASDAQ: VVOS · Real-Time Price · USD
3.120
-0.230 (-6.87%)
At close: Sep 26, 2025, 4:00 PM EDT
3.270
+0.150 (4.81%)
After-hours: Sep 26, 2025, 7:59 PM EDT

Company Description

Vivos Therapeutics, Inc. operates as a medical technology company that develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults.

It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring.

The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada.

Vivos Therapeutics, Inc. was founded in 2016 and is based in Littleton, Colorado.

Vivos Therapeutics, Inc.
Vivos Therapeutics logo
Country United States
Founded 2016
IPO Date Dec 11, 2020
Industry Medical Devices
Sector Healthcare
Employees 109
CEO R. Huntsman

Contact Details

Address:
7921 Southpark Plaza, Suite 210
Littleton, Colorado 80120
United States
Phone 844 672 4357
Website vivos.com

Stock Details

Ticker Symbol VVOS
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
IPO Price $6.00
CIK Code 0001716166
CUSIP Number 92859E108
ISIN Number US92859E2072
Employer ID 81-3224056
SIC Code 3841

Key Executives

Name Position
R. Kirk Huntsman Co-Founder, Chairman of the Board and Chief Executive Officer
Bradford K. Amman Chief Financial Officer, Treasurer and Secretary
Todd Huntsman Co-Founder and Senior Vice President of Product and Technology
RaeAnn Byrnes Co-Founder and Senior Vice President of Events and Clinical Advisory Services
Susan McCullough Co-Founder and Executive Vice President of Operations
Dr. Terry Jones Senior Vice President of Human Resources
Nicholas M. DeGennaro Senior Vice President of Mergers and Acquisition Group
Ruth Hembree Senior Vice President of Practice Services
John Ballard Senior Vice President of Technology
Michael E. Bruhn Executive Vice President of Business Operations Integration

Latest SEC Filings

Date Type Title
Sep 18, 2025 8-K Current Report
Sep 12, 2025 8-K Current Report
Sep 12, 2025 424B5 Filing
Sep 10, 2025 EFFECT Notice of Effectiveness
Sep 5, 2025 S-3/A [Amend] Registration statement under Securities Act of 1933
Aug 25, 2025 8-K/A [Amend] Current report
Aug 20, 2025 8-K Current Report
Aug 19, 2025 10-Q Quarterly Report
Aug 14, 2025 NT 10-Q Notification of inability to timely file Form 10-Q or 10-QSB
Jul 14, 2025 SCHEDULE 13G Filing